文献速递血管炎

巨细胞动脉炎治疗:从广谱免疫抑制剂到靶向治疗

Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

综述回顾巨细胞动脉炎(GCA)治疗从糖皮质激素到靶向药物的演变,指出甲氨蝶呤有 modest 疗效而抗TNF治疗无明确获益,托珠单抗阻断IL-6受体可有效维持缓解并减少糖皮质激素暴露且已获批,但近半数患者无获益,需探索更多选择。

要点

  • 糖皮质激素仍是GCA治疗基础,甲氨蝶呤有 modest 疗效。
  • 抗TNF治疗未显示明确获益。
  • 托珠单抗阻断IL-6受体有效维持缓解并减少激素暴露,已获批用于GCA。

核心结论

  • 托珠单抗阻断IL-6受体对维持GCA缓解和减少糖皮质激素暴露有效,且已获批用于GCA治疗。
  • 近半数GCA患者不能从托珠单抗获益,需要研究其他靶向治疗选择。

研究设计与样本

  • 综述,聚焦GCA的标准治疗方法和已研究或正在研究的靶向治疗。

主要发现

  • 数十年来GCA治疗依赖糖皮质激素。
  • 过去二十年工作支持甲氨蝶呤有 modest 疗效,但抗TNF治疗无明确获益。
  • 靶向特定细胞因子、细胞因子受体或信号通路的药物,结合对GCA免疫病理学的更好但仍有限的理解,正开辟进一步治疗可能性。

临床怎么用

  • 托珠单抗可用于维持GCA缓解并减少糖皮质激素暴露。
  • 对托珠单抗无获益的近半数患者,需考虑其他治疗选项。

局限性

  • 对GCA免疫病理学的理解仍有限。
  • 近半数患者对托珠单抗无获益,需研究额外选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For decades, the treatment of GCA has relied on glucocorticoids. Work over the past two decades has supported a modest efficacy of MTX but no clear benefit from anti-TNF-based therapies. More recently, the therapeutic armamentarium for GCA has expanded. The availability of agents targeting specific cytokines, cytokine receptors or signalling pathways, along with a better, although still limited, understanding of the immunopathology of GCA, are opening further therapeutic possibilities. Blocking IL-6 receptor with tocilizumab has been effective in maintaining remission and reducing glucocorticoid exposure and tocilizumab has been approved for the treatment of GCA. However, nearly half of the patients do not benefit from tocilizumab and additional options need to be investigated. This review focuses on standard therapeutic approaches and on targeted therapies that have been or are currently under investigation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cid MC, Ríos-Garcés R, Terrades-García N, et al. Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. Rheumatology (Oxford). 2020. PMID: 32348525. doi:10.1093/rheumatology/kez645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。